Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE:A) expanded its Altura HPLC column portfolio with new Altura size exclusion (SEC) and Altura PLRP-S columns for biotherapeutic analysis.
The columns use Ultra Inert technology to improve peak shape, sensitivity, aggregate recovery and conditioning across peptides, proteins, oligonucleotides, antibody-drug conjugates and other complex modalities, and are available globally.
Crawford & Company (NYSE:A) renewed its corporate membership with RISE (Rising Insurance Star Executives), underscoring a commitment to developing early-career insurance professionals. RISE offers mentorship, education, networking and leadership programs that help build future insurance leaders.
Crawford highlights this membership as part of a broader talent strategy that includes Broadspire’s Early Career and Global Technical Services’ Protégé Programs, internships, university partnerships and structured training through Crawford Educational Services.
Agilent (NYSE:A) launched xCELLigence RTCA eSight AI, an AI-powered software module for its RTCA eSight instrument. The module automates label-free imaging analysis, reducing manual cell segmentation and parameter tuning while supporting standardized, dual imaging and impedance readouts from the same cells.
It targets drug discovery and high-throughput biopharma research and builds on Agilent’s 2025 revenue base of $6.95 billion and approximately 18,000 employees worldwide.
Agilent (NYSE:A) completed its acquisition of Biocare Medical, a global clinical pathology provider, from an investor group led by Excellere Partners and GHO Capital Partners. Biocare joins Agilent’s Life Sciences and Diagnostics Markets Group.
According to Agilent, the deal is expected to be accretive to top-line growth, margin profile and non-instrument revenue mix in year one, and to EPS about 12 months after close. The company plans to outline the expected FY2026 financial impact in its third-quarter earnings release.
Crawford (NYSE:A) announced a leadership transition in its Middle East operations and new senior hires in the UAE.
Regional director Vic Noble will retire at the end of July 2026. Christopher Wylie becomes regional director from 22 June 2026, and senior adjusters Chris Burley and Steve Smith join in the UAE.
Agilent Technologies (NYSE:A) announced a collaboration with OpenAI and Boston Consulting Group (BCG) to deploy artificial intelligence across its products, operations, and customer workflows.
Initial AI use cases focus on enhancing customer experience and speeding the new product pipeline, with plans to expand efforts over the next 6–12 months.
Agilent (NYSE:A) received U.S. FDA approval to expand use of PD-L1 IHC 22C3 pharmDx (Code GE006) on the Dako Omnis platform. The test can now help identify esophageal squamous cell carcinoma, triple‑negative breast cancer, cervical cancer, and gastric or GEJ adenocarcinoma patients who may be eligible for treatment with KEYTRUDA.
This extends prior approvals in NSCLC and HNSCC and adds Dako Omnis alongside Autostainer Link 48. A multisite study met acceptance criteria for inter‑platform concordance, supporting consolidated, automated PD-L1 testing workflows.
TORM (NASDAQ: TRMD) increased its share capital by 28,144 A-shares through the exercise of Restricted Share Units from its incentive program. The new shares were subscribed in cash at prices of DKK 127.30, 139.90 and 195.50 per A-share.
After the capital increase, total share capital is USD 1,023,671.18, divided into 102,367,118 A-shares of nominal USD 0.01 each, with one vote per share. The new shares are ordinary, dividend‑entitled and are expected to be listed on Nasdaq Copenhagen.
Agilent (NYSE:A) announced OpenLab Sync, a Lab Execution System that digitally connects workflows from method design to bench execution. The system delivers guided, standardized, traceable procedures for regulated labs, integrates USP MethodConnect for machine-readable USP–NF content, and uses AI to streamline setup, integration, and monitoring.
Designed for pharmaceutical quality control and other regulated environments, OpenLab Sync supports data integrity, audit readiness, and scalable global workflows within the OpenLab ecosystem. According to Agilent, the company generated $6.95 billion revenue in fiscal 2025 and employs about 18,000 people worldwide.
Agilent (NYSE:A) reported second-quarter fiscal 2026 revenue of $1.83 billion, up 10.0% reported and 6.3% core year-over-year. GAAP EPS was $1.20 and non-GAAP EPS $1.49, rising 60% and 14% respectively.
The company raised fiscal 2026 guidance, now expecting revenue of $7.39–$7.49 billion and non-GAAP EPS of $6.00–$6.10. Q2 non-GAAP operating margin reached 26.4%, with all three business groups delivering reported revenue growth of 6–14%.